SERTM2 and amyotrophic lateral sclerosis: Given that GDNF is one of the critical targets for ongoing ALS clinical trials (Baloh et al, 2022), further study of the role of Sertm2 in spinal MNs and if it may be exploited as a biomarker and a new therapeutic target for ALS could prove illuminating.